Hangzhou Huadong Medicine Group Bioengineering Research Institute

Hangzhou Huadong Medicine Group Bioengineering Research Institute is the primary biotechnology R&D arm of Huadong Medicine, a leading Chinese pharmaceutical company. The institute focuses on the development of innovative biologics, including recombinant proteins, monoclonal antibodies, and antibody-drug conjugates (ADCs). It has established a strong presence in the metabolic disease space, notably with its GLP-1 receptor agonist portfolio featuring liraglutide and semaglutide. Additionally, the institute drives research in oncology, immunology, and nephrology, leveraging advanced microbial fermentation and protein engineering platforms. Its work supports the parent company's transition from a generic-focused manufacturer to an innovation-driven global biopharmaceutical player.